New pill recognition software has implications for emergency and clinical settings
April 16, 2012 By Steve Tokar in Medications
Saturday, 2 AM. A 911 dispatcher receives a frantic call: "I found my roommate passed out. I think she may have overdosed!"
But on what? Imagine if, when first responders arrive on the scene, they point a cell phone camera at pills scattered near the victim, and within seconds, they can know what drugs are likely involved.
In overdose cases like this, where there is uncertainty as to the identity of the pill, a new application could provide real-time identification in the field or emergency room, says Rahul C. Deo, MD, PhD, an assistant professor at UCSFs Cardiovascular Research Institute.
Deo is collaborating with UCSF medical student David Ouyang to develop a mobile application that can rapidly identify pills based on color, shape, and imprint. The project has received a significant boost from the T1 Catalyst Mobile Health Translational Project Award offered by the Clinical and Translational Science Institute (CTSI) at UCSF.
The CTSI T1 Catalyst mobile health grant is a tiered award that provides increasing benefit at each of three phases, beginning with feedback and analysis of all proposals. A selected number of awardees are then chosen to receive expert consultation from an exclusive panel of technical, clinical, and business experts. In the final phase, one team is awarded $30,000 to develop its early stage idea.
Deo and Ouyang, recipients of the final award, will use the funds to convert thedemonstration version of their software into a robust and user-friendly application for handheld devices.
According to Deo, there are a number of potential uses for the software, which can not only identify a pill, but access and display a wide range of information on the medication.
It could also assist with, or eliminate, manual entry of patient medications into electronic health records, which will help physicians as well as encourage patient participation, Deo says.
Also, in cases when hospital patients are given several medications simultaneously, the application could serve as a point-of-care verification step for those medications, he adds.
Deos research is focused on using genetics and bioinformatics to understand fundamental differences in cardiovascular disease processes among patients. He is also interested in applying large amounts of data toward the problem of individualizing patient treatments, he says.
Mobile health technologies have the potential of doing just that, with much more frequent recordings of heart rate and blood pressure, as well as environmental factors such as diet and exercise that we have a very hard time measuring otherwise.
Deos award points to the role played by CTSI and the T1 Catalyst mHealth grants in fostering, shaping and developing translational mHealth projects at UCSF, says S. Claiborne Clay Johnston, MD, PhD, director of CTSI and associate vice chancellor of research at UCSF.
Digital health is finally a huge growth area, says Johnston. It has taken a long time, but now this is a super-hot area for innovation. UCSF and its faculty are perfectly positioned to be contributing the great ideas that become standards a few years from now.
Provided by
University of California, San Francisco
-
UCSF experts highlight need for innovation in recruiting participants for clinical trials
Dec 23, 2011 |
not rated yet |
0
-
Market factors affect closures of emergency departments nationwide
Jun 10, 2011 |
not rated yet |
0
-
Researchers evaluate impact of July effect in teaching hospitals
Jul 13, 2011 |
not rated yet |
0
-
Simple, common BMI data stored in e-records can identify patients with heart disease risk
Mar 13, 2012 |
not rated yet |
0
-
Tracking proteins behaving badly provides insights for treatments of brain diseases
Mar 19, 2012 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
14 hours ago |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
15 hours ago |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Alzheimer's disease, the soft target of the euthanasia debate
(Medical Xpress)—The way Alzheimer's disease is portrayed by advocacy groups and the media is having undue influence on the euthanasia debate, according to a Deakin University nursing ethics professor.
Depression raises diabetics' risk of severe low blood sugar episodes
(Medical Xpress)—Patients with diabetes who are depressed are much more likely to develop episodes of dangerously low blood sugars, or hypoglycemia, than are those who are not depressed, a new study has ...
Ground breaking cancer research finds immune system link
(Medical Xpress)—Curtin University researchers have found evidence that targeting specific cells in the body can reverse the effects of cancer on the immune system.
Patenting the human genome
Can human genes be patented? That was the question posed by Alan J. Snyder, vice president and associate provost for research and graduate studies at Lehigh, and Lee Kaplan, scientific director of cellular and molecular genetics ...
New parenting program benefits ADHD children
A new program for treating the emotional health of mothers of children with ADHD has shown significant benefits for the children themselves, finds a new study by University of Maryland researchers. The program combines treatment ...
Cardiac study used as source for new guidelines on treating people undergoing coronary artery bypass surgery
Cardiac research from the University of Alberta had serious impact as a source for the American College of Cardiology and the American Heart Association's new guidelines on how to treat patients undergoing coronary artery ...